Micro-CT Based Experimental Liver Imaging Using a Nanoparticulate Contrast Agent: A Longitudinal Study in Mice by Boll, Hanne et al.
Micro-CT Based Experimental Liver Imaging Using a
Nanoparticulate Contrast Agent: A Longitudinal Study in
Mice
Hanne Boll
1, Stefanie Nittka
2, Fabian Doyon
3, Michael Neumaier
2, Alexander Marx
4, Martin Kramer
5,
Christoph Groden
1, Marc A. Brockmann
1*
1Department of Neuroradiology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, 2Department of Clinical Chemistry, Medical Faculty
Mannheim, University of Heidelberg, Mannheim, Germany, 3Department of Surgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany,
4Department of Pathology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, 5Small Animal Clinic, Department of Veterinary Clinical Sciences,
Justus-Liebig-University, Giessen, Germany
Abstract
Background: Micro-CT imaging of liver disease in mice relies on high soft tissue contrast to detect small lesions like liver
metastases. Purpose of this study was to characterize the localization and time course of contrast enhancement of a
nanoparticular alkaline earth metal-based contrast agent (VISCOVER ExiTron nano) developed for small animal liver CT imaging.
Methodology: ExiTron nano 6000 and ExiTron nano 12000, formulated for liver/spleen imaging and angiography,
respectively, were intravenously injected in C57BL/6J-mice. The distribution and time course of contrast enhancement were
analysed by repeated micro-CT up to 6 months. Finally, mice developing liver metastases after intrasplenic injection of colon
carcinoma cells underwent longitudinal micro-CT imaging after a single injection of ExiTron nano.
Principal Findings: After a single injection of ExiTron nano the contrast of liver and spleen peaked after 4–8 hours, lasted up
to several months and was tolerated well by all mice. In addition, strong contrast enhancement of abdominal and
mediastinal lymph nodes and the adrenal glands was observed. Within the first two hours after injection, particularly
ExiTron nano 12000 provided pronounced contrast for imaging of vascular structures. ExiTron nano facilitated detection of
liver metastases and provided sufficient contrast for longitudinal observation of tumor development over weeks.
Conclusions: The nanoparticulate contrast agents ExiTron nano 6000 and 12000 provide strong contrast of the liver, spleen,
lymph nodes and adrenal glands up to weeks, hereby allowing longitudinal monitoring of pathological processes of these organs
in small animals, with ExiTron nano 12000 being particularly optimized for angiography due to its very high initial vessel contrast.
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Introduction
Non-invasive longitudinal monitoring of pathological processes
in small animal models using micro-computed tomography
(micro-CT) has gained increasing importance within the last
decade [1]. For micro-CT imaging of liver disease in small
animals, high soft tissue contrast is required in order to detect
small pathological lesions such as liver metastases. For this
purpose, contrast agents providing a positive contrast of the liver
have been developed for use in micro-CT in small animals
[2,3,4,5,6,7,8,9,10,11,12,13,14]. Since the hitherto used contrast
agents have relatively short elimination times on the order of hours
and up to a few days, they generally have to be injected time and
again prior to each examination [2,4,14,15]. As repeated tail vein
injections in mice are time-consuming, a burden for the animal
and still include the risk of false injection, a longer-lasting contrast
of the liver would be preferable for fast, easy, and repetitive micro-
CT studies in small animal models of liver disease.
In the present study the time-course and distribution of contrast
enhancement after a single intravenous (i.v.) injection of a
nanoparticular contrast agent in mice is characterized. Further-
more, the use of the contrast agent for the detection of liver
metastases in mice using micro-CT is demonstrated.
Materials and Methods
Alkaline earth metal-based nanoparticulate contrast
agent
The contrast agent used in the present study (Viscover
TM
ExiTron
TM nano; Miltenyi Biotec, Bergisch-Gladbach, Germany)
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specifically formulated for pre-clinical computed tomography
imaging. The nanoparticles are sterically stabilized by a polymer
coating and have a mean hydrodynamic diameter of 110 nm.
Upon i.v. injection, ExiTron nano circulates in the blood stream
and is taken up by cells of the reticuloendothelial system (RES),
including macrophages within the liver, the so-called Kupffer
cells. Two different formulations of the contrast agent are
available and both were used in the underlying study: ExiTron
nano 6000 (optimized for liver/spleen imaging) and ExiTron
nano 12000 (optimized for angiography) with densities of the
undiluted contrast agents prior to injection of approx. 6000 HU
and approx. 12000 HU, respectively. The injected volume of
100 ml ExiTron nano per mouse (25g) corresponds to a dose
equivalent to 640 mg iodine/kg body weight or 1200 mg iodine/
kg body weight for ExiTron nano 6000 and ExiTron nano
12000, respectively.
Anaesthesia, intubation, and micro-CT imaging of mice
All experiments were carried out after receiving the local ethics
committee approval (Regierungspra ¨sidium Karlsruhe; G-202/10).
Institutional guidelines for animal welfare and experimental
conduct were followed. The animals were anesthetized by
isoflurane (Forene; Servopharma GmbH, Oberhausen, Germany)
inhalation (3% for induction and 1–2% for maintenance) and
transferred to a prewarmed animal operation warmth plate
(MEDAX GmbH, Neumuenster, Germany). A catheter for i.v.
injection of the contrast agent was inserted as previously described
[16]. Briefly, a mouse-tourniquet was tightened over the base of
the tail and a 27-gauge i.v. catheter (pre-flushed with a heparin
solution) was inserted into a lateral tail vein and fixed with tape.
To reduce artefacts arising from respiratory motion, for some of
the CT scans the mice were intubated and ventilated as described
previously [17,18]. Briefly, for intubation, mice were placed supine
on a tilted heating plate. A strong light source allowed
transillumination of the trachea. The tongue was gently pulled
out in order to reveal a view on the vocal cords. A shortened
neuroradiological wire guide with an extremely soft tip (Mirage
0.008 in.; Micro Therapeutics, Grenoble Cedex, France) was used
for atraumatic intubation. A 22-G i.v. catheter (Klinika Medical
GmbH, Germany) was modified by attaching a silicone wedge as
described by MacDonald et al. [19] and pushed over the guide
wire using Seldingers technique. The endotracheal tube was
connected to a small animal ventilator (Small Animal Ventilator
KTR5; Hugo Sachs Elektronik-Harvard Apparatus, March-
Hugstetten, Germany) and mice were ventilated at a respiratory
rate of 100 breaths per minute with a ventilatory tidal volume of
0.2 ml. Relaxation by i.p. injection of 1.5 mg/kg body weight
Rocuronium (EsmeronH; EssexPharma, Munich, Germany) al-
lowed single-breath-stop micro-CT within 40 s scan time (as
described below). Relaxation afterwards was reversed by i.p.
injection of 20 mg/kg body weight of Sugammadex (BridionH;
EssexPharma).
For micro-CT imaging the mice were fixed in a custom-made
acrylic cradle that was mounted onto the three-jaw drill chuck of
the rotational axis of the micro-CT. An industrial x-ray inspection
system (Yxlon Y.Fox; Yxlon International GmbH, Hamburg,
Germany) was used. The system was equipped with a multifocus
cone beam x-ray source with a diamond-coated high-power
tungsten target and a 12-bit direct digital flat bed detector (Varian
PaxScan 2520; Varian, Palo Alto, CA, USA). The tube
parameters were set to 80 kV and 75 mA (focal spot size 5 mm).
The scanning protocol was programmed to acquire images at 30
frames per second (fps) while continuously rotating the mouse by
190u (180u plus 10u cone beam angle) within 40 seconds scan time,
resulting in a total of 1200 projections per scan [20]. The
projections were reconstructed using a filtered backprojection
algorithm with a matrix of 51265126512 using the software
provided by the manufacturer of the micro-CT (Reconstruction
Studio; Yxlon International GmbH).
Characterization of the time course of contrast
enhancement
In the first part of the study, the time course of the uptake of two
formulations of 100 ml of ExiTron nano (ExiTron nano 6000 and
ExiTron nano 12000; n=3 for each group) by the RES of the liver
and spleen was assessed in healthy C57BL/6J mice.
Since our micro-CT does not provide Hounsfield units, we
measured the relative increase of the contrast enhancement
compared to a baseline level. More exactly, the density of the
liver and vessels in non-enhanced images was set to 100%.
After injection of the contrast agent repetitive micro-CT scans
were performed at different time points (as described in the
results section) for up to 6 months. The distribution pattern
and the relative density (in % as compared to the non-
enhanced baseline levels) of the contrast agent within the
vascular system (ROI measurements performed within the left
ventricle) and the liver (ROI measurements performed
avoiding large intrahepatic vessels) were analysed. During this
period mice were weighed and checked for their well-being
every other day.
Mouse model of liver metastasis
To test the feasibility of the detection of liver metastases using
the nanoparticular contrast agent, intrasplenic injection of MC38
or C15-A.3 colon carcinoma cells was performed in anesthetized
C57BL/6 Han TgN (CEAgen) HvdP mice expressing the human
Carcinoembryonic antigen (CEA) as a transgene. MC38 is a
sygeneic Methyl-Cholanthren-induced colon cancer line, while
C15-A.3 is a MC38-derivative cell line transfected with the
CEACAM5 gene coding for the human Carcinoembryonic
antigen (CEA). In some of the mice receiving MC38 cells a
splenectomy was performed 7 days after tumor cell injection in
order to prevent rupture of the spleen due to the rapid primary
tumor growth before the development of liver metastases.
Since the time until development of liver metastases varied,
repetitive scans were performed to detect liver metastases and to
monitor tumor growth. For this purpose, micro-CT examinations
were performed after a single intravenous injection of 100 ml
ExiTron nano 6000 (15 mice) or 100 ml ExiTron nano 12000 (15
mice) prior to the first micro-CT scan, which was performed on
day 9 after splenic tumor engraftment.
Image analysis
Analysis of reconstructed images was performed using the
public domain software OsiriX (v3.5.1; www.osirix-viewer.com).
For characterization of the time course of liver uptake and
intravascular contrast, ROIs (regions of interest) were placed in
coronal slices of the liver and the left ventricle. While
positioning ROIs in the liver, care was taken to avoid large
liver vessels, as this could artificially influence liver tissue values.
T h ev a l u e sw e r ea v e r a g e d( m e a n 61SD) to achieve the vessel
and liver CT contrast enhancement curves for both ExiTron
nano 6000 and ExiTron nano 12000. In mice developing liver
metastases the diameter of the liver lesions was measured using
OsiriX software and the smallest identifiable liver metastasis was
determined.
Nanoparticular CT-Contrast Agent for Mice
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Time course characterization of contrast enhancement
All mice tolerated the injection of both formulations of ExiTron
nano well and even after 6 months post injection of the contrast
agent were no adverse effects, such as weight loss or abnormal
behaviour, observed.
Two minutes post injection of ExiTron nano 6000 and 12000
the vessel density peaked, and subsequently halved after
60 minutes or 4 hours, respectively (Fig. 1). At both concentra-
Figure 1. Time course of contrast enhancement within the vascular system and the liver of C57BL/6J mice (n=3 per group) after a
single i.v. injection of 100 ml ExiTron nano 6000 or ExiTron nano 12000. Measurements were performed by placing a ROI within the left
ventricle (vessel contrast) and within the liver avoiding large intrahepatic vessels. The baseline level (=100%) refers to measurement of the relative
density of the liver and the vascular system prior to administration of contrast agent.
doi:10.1371/journal.pone.0025692.g001
Figure 2. A shows a volume rendering of a mouse 30 minutes after i.v. injection of ExiTron nano 12000. B is a curved maximum
intensity projection in coronal orientation of the same scan. A and B demonstrate the feasibility to perform CT angiography during the early
intravascular phase of the tested contrast agent. Additionally, A and B show the early contrast agent uptake by the RES with increasing contrast of
liver and spleen. C is a coronally oriented curved maximum intensity projection of a mouse that did not receive contrast agent.
doi:10.1371/journal.pone.0025692.g002
Nanoparticular CT-Contrast Agent for Mice
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provided the stronger contrast (Fig. 2), and a more prolonged time
window for vessel imaging of up to 4–8 hours after contrast agent
injection. Vessel contrast returned to baseline values 4 or 24 hours
after injection of ExiTron nano 6000 or 12000, respectively.
While the intravascular contrast decreased, liver contrast
increased and reached its peak 4 h after injection of ExiTron
nano 6000 and 8 h after injection of ExiTron nano 12000. The
initially observed rapid increase (small plateau) of liver contrast
observed 2–10 minutes after injection of ExiTron nano 6000 and
12000 is not only attributable to early uptake by the RES of the
liver but also to the presence of contrast agent located within the
vascular system of the liver. Liver imaging was feasible even after
more than 200 days post administration of a single injection of
ExiTron nano 6000 or 12000.
In addition to contrast enhancement of liver and spleen, we
most interestingly observed contrast enhancement of the abdom-
inal and mediastinal lymph nodes, mainly located in the marginal
area of the nodes after injection of both formulations of ExiTron
nano (Fig. 3C). We furthermore also identified evident contrast
enhancement of the adrenal glands, mainly located in the cortex
and here predominantly within the zona reticularis (Fig. 3D). As
an incidental finding in one mouse we observed diaphragmatic
herniation of a part of the left medial liver lobe, which was
distinctively delimited from the adjacent heart tissue due to use of
the liver-specific contrast agent (Fig. 4A and 4B). Figures 4C and
4D were inlcuded to provide a comparison of the liver in an
animal before (Fig. 4C) and 24h after i.v. administration of 100 ml
ExiTron nano 6000 (Fig. 4D).
Monitoring development of liver metastasis by repetitive
micro-CT
Longitudinal monitoring of liver lesions was feasible after a
single injection of ExiTron nano 6000 (Fig. 5A-D). Liver
metastases did not take up the contrast agent, making them
clearly detectable as unenhanced regions within the hyperdense
healthy liver tissue. The smallest detectable liver metastases
measured approx. 300 mm in diameter (Fig. 5A). The strong
contrast enhancement additionally allowed delineation of intra-
splenic tumors (* in 3A and 3B). As reported in the methods
section, some mice underwent splenectomy due to massive
intrasplenic tumor growth in order to allow further monitoring
of liver metastases: in these animals we observed liver uptake of
ExiTron nano to be increased by approx. 15% (p.0.05).
Discussion
Micro-CT imaging of small liver lesions in mice relies on the use
of contrast agents to compensate for the insufficient soft tissue
contrast in non-enhanced liver tissue. While contrast agents are
normally used to contrast the pathological process itself, in liver
imaging contrast agents are frequently used to increase the
contrast of cells located within the healthy liver tissue, hereby
visualizing pathological processes as unenhanced regions within
the contrasted liver tissue [4,5,6,7,8,13,14,21]. To identify very
small liver lesions, a contrast agent needs to provide a possibly
strong and specific contrast of the liver tissue. Since in animal
experiments longitudinal measurements of pathologic lesions are
frequently performed to investigate pathological processes and to
monitor the efficacy of all kinds of therapeutic regimens, it would
be ideal if a long-lasting contrast could be obtained after a single
injection of the contrast agent, hereby eliminating the need for
time-consuming and cumbersome repeated tail vein injections.
In this study we present the first results using two novel alkaline
earth metal-based nanoparticulate contrast agents (ExiTron nano
6000 and 12000) for preclinical computed tomography, which
were found to provide a strong contrast of the liver lasting up to 6
months. The tested contrast agents differ in several aspects from
other commercially available contrast agents. Firstly, contrast of
the liver and spleen were achieved by uptake of the nanoparticles
by the RES, while other most frequently used contrast agents are
selectively taken up by hepatocytes via an apolipoprotein E (ApoE)
receptor-mediated pathway [6,8,12]. Most interestingly, we found
that besides liver and spleen uptake, the agent also provided strong
contrast of the abdominal and mediastinal lymph nodes as well as
of the adrenal glands, mainly in the zona reticularis between the
cortex and the medulla. While liver and splenic uptake can be
explained by RES-mediated uptake of nanoparticles, the reason
for the observed contrast enhancement in the periphery of the
lymph nodes (Fig. 3C) and in the adrenal glands (Fig. 3D) can be
expected to be due to macrophages, as discussed by Weinmann
et al [22].
A similar contrast agent biodistribution has, to the authors’ best
knowledge, not been described before in mouse studies. We have,
however, experienced that other contrast agents, e.g. Fenestra LC,
also result in a relatively weak and infrequent enhancement of the
lymph nodes and adrenal glands (unpublished data of our
Figure 3. A and B show intrasplenic (*) and intrahepatic (LMet)
growing tumors 26 days after intrasplenic injection of C15A3
colon tumor cells. A and B were acquired 4 hours after i.v. injection of
100 ml ExiTron nano 12000. B, C, and D illustrate contrast enhancement
of the abdominal and mediastinal lymph nodes (LN) and of the adrenal
glands (AdrG). C was acquired 4 hours after i.v. injection of 100 ml
ExiTron nano 12000; D was acquired 22 days after i.v. injection of 100 ml
ExiTron nano 12000. Micro-CT scanning parameters: 40 sec scan time;
190u rotation; 1200 projections; voxel size 41641655 mm
3.
doi:10.1371/journal.pone.0025692.g003
Nanoparticular CT-Contrast Agent for Mice
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injection of Fenestra LC in a model of metastatic pheochromo-
cytoma [13], and reported that adrenal gland lesions were usually
undetectable on micro-CT unless they were large and growing
into the contrast-enhanced liver area, corroborating our observa-
tions.
The second difference compared to other liver contrast agents is
the smaller injection volume required. Especially in mice, which
have a total blood volume in the range of 1200–1500 ml, the
injection of larger volumes of a contrast agent can be problematic.
Thus, an injection volume of 100 ml is much more preferable over
injection volumes between 200 ml and up to 1500 ml, which are
usually recommended for iodine-based contrast agents [3,4,6,7,
8,14,15,23,24,25] to provide sufficient contrast of the liver. The
reduced injection volume is facilitated by the high concentration of
the alkaline earth metal, which is possible due to the contrast
agents’ nanoparticulate formulation.
Due to the strong contrast of ExiTron nano and the slightly
delayed uptake by the RES, not only imaging of the liver and
spleen but also visualization of the vasculature was feasible directly
after injection of the contrast agent and up to 30 minutes (ExiTron
nano 6000) or 240 minutes (ExiTron nano 12000) post injection.
These time windows are similar to those of other frequently used
blood pool contrast agents [23]; however, the latter require
unfavorable higher injection volumes to obtain similar contrast.
Though vessel imaging was feasible with both ExiTron nano 6000
and ExiTron nano 12000, ExiTron nano 12000 was preferable
due to its higher contrast and increased time window.
Imaging of the liver was possible from about 30 minutes after
contrast agent injection, with the contrast peaking after 4–8 hours
and lasting up to several weeks and months, which greatly differs
to other contrast agents where liver contrast values return to
baseline levels within a few days after the injection [3,5,6,
9,10,11,21,26]. Though significant liver contrast was reported as
persisting for example, for 1 week [3] and up to 15 days [6] after a
single injection of Fenestra LC, image quality at these late time
points was reduced. In our study the smallest detectable liver
metastasis measured approx. 300 mm in diameter.
To conclude, the nanoparticulate contrast agents ExiTron nano
6000 and 12000 provide rapid, strong and specific contrast of the
RES of the liver and the spleen at low injection volumes. Due to
the long-lasting contrast of the liver up to several weeks after
injection, ExiTron nano allows longitudinal imaging of e.g.
developing liver metastasis after a single injection of the contrast
agent, which saves time and reduces additional stress for the
animals. The high intravascular contrast up to 4–8 hours after
injection of the contrast agent furthermore allows this contrast
agent to be employed in the field of vascular imaging. Finally,
strong enhancement of lymph nodes and adrenal glands renders
this contrast agent an interesting tool for future studies of these
organs in small animal models.
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Figure 5. Repeated micro-CT of a mouse illustrates develop-
ment of liver metastases 9, 12, 14, and 19 days after
intrasplenic injection of MC38 colon tumor cells. Smallest
detectable liver metastases (arrows) measured 300 mm in diameter.
doi:10.1371/journal.pone.0025692.g005
Figure 4. A and B show a partial diaphragmatic herniation of
the left upper liver lobe in coronally (A) and sagittally (B)
reconstructed maximum intensity projections of a C57BL/6J
mouse 22 hours after i.v. injection of 100 ml ExiTron nano
12000. The herniated liver tissue can be easily delimited from the
adjacent heart due to the positive liver contrast. C and D are micro-CT
scans of the murine liver before (C) and 24 hours after (D) intravenous
administration of 100 ml ExiTron nano 6000.
doi:10.1371/journal.pone.0025692.g004
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